利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

41 条记录 (耗时 0.022 秒)

    Treatment of Crohn's disease with laquinimod
    31.
    发明授权
    Treatment of Crohn's disease with laquinimod 有权
    用laquinimod治疗克罗恩病

    公开(公告)号：US08598203B2

    公开(公告)日：2013-12-03

    申请号：US12804795

    申请日：2010-07-29

    申请人： Nora Tarcic ,  Asi Haviv ,  Eran Blaugrund ,  Joel Kaye

    发明人： Nora Tarcic ,  Asi Haviv ,  Eran Blaugrund ,  Joel Kaye

    IPC分类号： A61K31/47 ,  A61K9/48

    CPC分类号： A61K31/4704 ,  A61K9/0053 ,  A61K9/48 ,  A61K31/519 ,  A61K31/52 ,  A61K31/573 ,  A61K31/58 ,  A61K31/606 ,  A61K45/06 ,  C07D215/56

    摘要： This application provides for a method of treating a subject suffering from Crohn's disease, the method comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This application provides for use of laquinimod in the manufacture of a medicament for treating a subject suffering from Crohn's disease. This application also provides for a pharmaceutical composition comprising laquinimod for use in treating a subject suffering from Crohn's disease.

    摘要翻译： 本申请提供了治疗患有克罗恩病的受试者的方法，所述方法包括向受试者周期性施用一定量的有效治疗受试者的拉喹莫德或其药学上可接受的盐。 本申请提供了用于制备用于治疗患有克罗恩病的受试者的药物的拉喹莫德。 本申请还提供了包含用于治疗克罗恩病患者的拉喹莫德的药物组合物。

    Use of ladostigil for the treatment of multiple sclerosis
    32.
    发明申请
    Use of ladostigil for the treatment of multiple sclerosis 审中-公开
    使用ladostigil治疗多发性硬化

    公开(公告)号：US20060276537A1

    公开(公告)日：2006-12-07

    申请号：US11443880

    申请日：2006-05-31

    申请人： Tamar Goren ,  Eran Blaugrund

    发明人： Tamar Goren ,  Eran Blaugrund

    IPC分类号： A61K31/325

    CPC分类号： A61K31/27 ,  A61K31/325

    摘要： Disclosed are methods for the treatment of a form of multiple sclerosis comprising administering an amount of R(+)-6-(N-methyl, N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof.

    摘要翻译： 公开了治疗多发性硬化症形式的方法，包括给予一定量的R（+） - 6-（N-甲基，N-乙基 - 氨基甲酰氧基）-N'-炔丙基-1-氨基茚满或其药学上可接受的盐 。

    USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNF THERAPY
    35.
    发明申请
    USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNF THERAPY 有权
    用于治疗败血症患者的LAQUINIMOD治疗失败的第一线抗TNF治疗

    公开(公告)号：US20130203807A1

    公开(公告)日：2013-08-08

    申请号：US13757004

    申请日：2013-02-01

    申请人： Nora Tarcic ,  Asi Haviv ,  Eran Blaugrund ,  Joel Kaye

    发明人： Nora Tarcic ,  Asi Haviv ,  Eran Blaugrund ,  Joel Kaye

    IPC分类号： A61K31/4704

    CPC分类号： A61K31/4704 ,  A61K45/06 ,  C07D215/56

    摘要： This application provides for a method of treating a human patient afflicted with anti-TNFα refractory Crohn's disease, of treating a human patient afflicted with non-fibrostenotic Crohn's disease, and of treating a human patient whose Crohn's disease had not been surgically treated, the method comprising periodically administering to the patient an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the patient. This application also provides for a method of inducing or maintaining clinical remission in a human patient afflicted with Crohn's disease comprising periodically administering to the patient an amount of laquinimod effective to induce or maintain clinical remission in the patient, which amount of laquinimod is less than 0.5 mg/day.

    摘要翻译： 本申请提供了治疗患有抗TNFα难治性克罗恩病的人类患者，治疗患有非纤维化性克罗恩病的人类患者以及治疗其克罗恩病未经手术治疗的人类患者的方法，该方法 包括向患者定期施用一定量的有效治疗患者的拉喹莫德或其药学上可接受的盐。 本申请还提供了诱导或维持患有克罗恩病的人类患者的临床缓解的方法，其包括向患者定期施用一定量的有效诱导或维持患者临床缓解的拉喹莫德，该量的拉喹莫德小于0.5 mg /天。

    Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNF therapy
    39.
    发明授权
    Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNF therapy 有权
    使用拉喹莫德治疗一线抗TNF治疗失败的克罗恩病患者

    公开(公告)号：US09161935B2

    公开(公告)日：2015-10-20

    申请号：US13757004

    申请日：2013-02-01

    申请人： Nora Tarcic ,  Asi Haviv ,  Eran Blaugrund ,  Joel Kaye

    发明人： Nora Tarcic ,  Asi Haviv ,  Eran Blaugrund ,  Joel Kaye

    IPC分类号： A61K31/47 ,  A61K9/48 ,  A61K31/4704

    CPC分类号： A61K31/4704 ,  A61K45/06 ,  C07D215/56

    摘要： This application provides for a method of treating a human patient afflicted with anti-TNFα refractory Crohn's disease, of treating a human patient afflicted with non-fibrostenotic Crohn's disease, and of treating a human patient whose Crohn's disease had not been surgically treated, the method comprising periodically administering to the patient an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the patient. This application also provides for a method of inducing or maintaining clinical remission in a human patient afflicted with Crohn's disease comprising periodically administering to the patient an amount of laquinimod effective to induce or maintain clinical remission in the patient, which amount of laquinimod is less than 0.5 mg/day.

    摘要翻译： 本申请提供了治疗患有抗TNFα难治性克罗恩病的人类患者，治疗患有非纤维化性克罗恩病的人类患者以及治疗克罗恩病未经手术治疗的人类患者的方法，该方法 包括向患者定期施用一定量的有效治疗患者的拉喹莫德或其药学上可接受的盐。 本申请还提供了诱导或维持患有克罗恩病的人类患者的临床缓解的方法，其包括向患者定期施用一定量的有效诱导或维持患者临床缓解的拉喹莫德，该量的拉喹莫德小于0.5 mg /天。

    Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
    40.
    发明授权
    Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate 失效
    用联合拉喹莫德和甲氨蝶呤治疗类风湿关节炎

    公开(公告)号：US08501766B2

    公开(公告)日：2013-08-06

    申请号：US13039188

    申请日：2011-03-02

    申请人： Joel Kaye ,  Eran Blaugrund ,  Nora Tarcic

    发明人： Joel Kaye ,  Eran Blaugrund ,  Nora Tarcic

    IPC分类号： A01N43/42 ,  A01N43/90 ,  A61K31/44 ,  A61K31/519

    CPC分类号： A61K31/4704 ,  A61K31/519 ,  A61K2300/00

    摘要： This invention provides a method of treating a subject afflicted with rheumatoid arthritis comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof and an amount of methotrexate, wherein the amounts when taken together are effective to treat the subject. This invention also provides laquinimod or pharmaceutically acceptable salt thereof for use in combination with methotrexate in treating a subject afflicted with rheumatoid arthritis. This invention also provides a pharmaceutical composition comprising an amount of laquinimod or pharmaceutically acceptable salt thereof and an amount of methotrexate for use in treating a subject afflicted with rheumatoid arthritis.

    摘要翻译： 本发明提供了治疗患有类风湿性关节炎的受试者的方法，其包括向所述受试者周期性施用一定量的拉喹莫德或其药学上可接受的盐和一定量的甲氨蝶呤，其中所述量一起有效治疗受试者。 本发明还提供了用于与甲氨蝶呤组合用于治疗患有类风湿性关节炎的受试者的拉喹莫德或其药学上可接受的盐。 本发明还提供了包含一定量的拉喹莫德或其药学上可接受的盐和用于治疗患有类风湿性关节炎的受试者的甲氨蝶呤的量的药物组合物。